このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Zhejiang Huahai Pharmaceutical マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Bao Hua Chen

最高経営責任者

CN¥2.2m

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	25.5%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

CEO（最高経営責任者

Bao Hua Chen (62 yo)

no data

在職期間

CN¥2,180,000

報酬

Mr. Bao Hua Chen serves as the President of TCM BU at Shanghai Pharmaceutical (Group) Co., Ltd. Mr. Chen serves as General Manager and Director at Zhejiang Huahai Pharmaceutical Co., Ltd and serves as its...

Zhejiang Huahai Pharmaceutical マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 25%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in 2Q 2023)

Dividend reduced to CN¥0.20

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.12 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.57 (vs CN¥0.81 in FY 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 17%

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.16 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.34 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.053 in 3Q 2021)

Investor sentiment improved over the past week

Zhejiang Huahai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.56 billion in funding

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.34 (vs CN¥0.64 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.053 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.24 in 2Q 2020)

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521) announces an Equity Buyback for CNY 200 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.15 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.41 in FY 2019)

New 90-day low: CN¥28.88

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.18

New 90-day low: CN¥31.49

Third quarter earnings released

Zhejiang Huahai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 20, 2020

New 90-day low: CN¥31.92

First half earnings released

New 90-day high - CN¥44.83

New 90-day high - CN¥40.55

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /14